New U.S. Department of Health and Human Services Campaign Joins HBCU Tour to Increase Flu, COVID-19 Vaccinations
September 10, 2024 12:21 ET
|
Risk Less. Do More. Pan Respiratory Virus Public Education Campaign
Milwaukee, Wis., Sept. 10, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Health and Human Services’ (HHS) Risk Less. Do More. campaign is partnering with the HBCU Tailgate Tour to increase...
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Moderna, Inc. (NASDAQ: MRNA); Investors with Losses Encouraged to Discuss Their Options with Counsel
August 27, 2024 12:10 ET
|
DiCello Levitt LLP
SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of purchasers or acquirers of Moderna, Inc. (NASDAQ: MRNA) (“Moderna” or the “Company”) securities...
Airfinity US RSV vaccine market estimate cut by 64% from $4.7bn to $1.7bn a year by 2030 following recommendations for single lifetime shot for elderly people
July 24, 2024 02:00 ET
|
Airfinity
London, England, July 24, 2024 (GLOBE NEWSWIRE) -- Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (RSV) for older adults in the US from $4.7bn per year...
Foundation for Sarcoidosis Research and Walgreens Unite in Alabama to Boost Sarcoidosis Awareness and Spring Vaccine Education for April Awareness Month
April 15, 2024 18:31 ET
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research Partners with Walgreens in Alabama to Raise Awareness for Sarcoidosis and Spring Vaccines
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 06, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
January 02, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
December 12, 2023 02:05 ET
|
Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
December 12, 2023 02:00 ET
|
Icosavax, Inc.
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023 16:05 ET
|
Icosavax, Inc.
- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023...
FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio
September 13, 2023 13:34 ET
|
FFF Enterprises.com
TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with...